HUTCHMED (China) Limited

19.19 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

HUTCHMED (China) Limited stock is up 11.18% since 30 days ago. The next earnings date is Jul 31, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 July’s closed higher than June.

About HUTCHMED (China) Limited

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and gastric cancer (GC) In addition, it develops Tazemetostat, an inhibitors of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients.